Table 1.

Selected publications on the use of electrochemotherapy in the treatment of melanoma

Author (year)	Number of patients	Number of lesions	Drug applied/delivery route	Number of ECT courses	Response to treatment				Follow-up	Local tumor control rate
					Complete (CR) (%)	Partial (PR) (%)	Stabilization(SD) (%)	Progression(PD) (%)
Scarlatos et al. 2011 [19]	5	ND	bleomycin i.v. or i.t.	7 (avg. 1.4)	60	40	0	0	60 days	ND
Gaudy et al. 2006 [17]	12	30	bleomycin i.t.	ND	36	10	29	25	min. 12 weeks	ND
Marty et al. 2006 [9]	20	98	bleomycin i.v. or i.t.; cisplatin i.t.	ND	66.3	14.3	ND	ND	min. 60 days, average of 133 days (from 60 to 380 days)	ND
Mir-Bonafe et al. 2014 [42]	31	ND	bleomycin i.v.	57 (avg. 1.54) from 1 to 3 courses	23	49	0	28	360 days	ND
Kreuter et al. 2014 [43]	20	ND	bleomycin i.v.	46 (avg. 2.3)	20	30	20	30	ND	ND
Ricotti et al. 2014 [18]	30	654	bleomycin i.v.	Avg. 1.32	20	80	0	0	min. 4 weeks, average of 20 months	LTCR 72% after 24 months
Solari et al. 2014 [23]	20	ND	bleomycin i.v.	ND	10	45	15	30	6 months	ND
Caraco et al. 2013 [20]	60	ND	bleomycin i.v.	100 (avg. 1.66) from 1 to 5 courses	48.4	38.3	0	13.3	min.3 months, average of 27.5 months	CR 27.7% after 27.5 months
Campana et al. 2009 [44]	34	373	bleomycin i.v or i.t.	ND	50	ND	ND	ND	min. 8 weeks, average of 9 months	ND
Quaglino et al. 2008 [22]	14	233	bleomycin i.v.	24 (avg. 1.71)	50	43	7	0	min. 8 weeks, average of 21 months	LTCR 74.5% after 24 months
Campana et al. 2012 [21]	85	268	bleomycin i.v, i.t. or combination	226 (avg. 2.66)	48	44	6	1,9	min 4 weeks, average of 26 months	LPFS after 24 months 87%
Kunte et al. 2017 [24]	151	394	bleomycin i.v. or i.t.	188 (avg. 1.3)	58	19	20	2 (1% not evaluable)	min. 60 days, average 116 days	OR 73% after 60 days
Total/average	502	2050			40.1	34
~OR = 74%

i.v. – intra venous; i.t. – intra tumorally; ND – no data